Medical Updates

Comparative Analysis of Pharmacotherapy for OAB Symptoms

Although antimuscarinic drugs and the beta 3 agonist mirabegron have been the mainstay of therapy for overactive bladder (OAB), there is lack of...

31 Oct, 2019

Email this page
Evaluation of 2 Dosage Regimens of Fosfomycin Prophylaxis in Patients Undergoing Transrectal Prostate Biopsy

This study evaluated the efficacy and safety of a prostate biopsy protocol using 2 vs 3 fosfomycin doses. Results indicated that both the dosage...

25 Oct, 2019

Email this page
Survival Outcomes with Sipuleucel-T Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

Safety and survival outcomes with sipuleucel-T immunotherapy for metastatic castration-resistant prostate cancer (mCRPC) have been analyzed in the...

16 Sep, 2019

Email this page
Visual Prostate Symptom Score Might be a Good Alternative to IPSS in Assessment of Lower Urinary Tract Symptoms

The Visual Prostate Symptom Score (VPSS), which uses pictograms to illustrate some of the questions addressed in International Prostate Symptom...

11 Sep, 2019

Email this page

Key Trials

Daily Tadalafil More Effective than On-Demand Tadalafil in Long-Term Treatment of Erectile Dysfunction

Tadalafil daily was associated with better efficacy than on-demand tadalafil in men with erectile dysfunction after at least 24 weeks of treatment....

Addition of Docetaxel to Androgen Deprivation Therapy Improves Survival Outcomes and is Cost-Effective in Metastatic Prostate Cancer

The survival outcomes associated with addition of docetaxel to androgen deprivation therapy (Doc-ADT) were superior compared to maximum androgen-...

Apalutamide Prolongs Survival in Metastatic Castration-Sensitive Prostate Cancer: Findings of TITAN Trial

Addition of enzalutamide to androgen deprivation therapy (ADT) significantly prolonged the overall survival and radiographic progression-free...

Addition of Enzalutamide to Standard First-Line Therapy Prolongs Survival in Metastatic Prostate Cancer

Addition of enzalutamide to standard first line therapy significantly prolonged the overall survival, PSA progression-free survival (PFS) and...

Slide Library

Tadalafil (Tadaflo)

Erectile dysfunction (ED) and the signs and symptoms of benign prostatic hyperplasia (BPH), are prevalent disorders in middle-aged and older men...

Email this page
Cranberry + D-mannose (Cranfit)

Around 50% of women experience at least one episode of UTI at some point in their lifetime and recurrent UTI occur in about 20-40% of women....

Email this page
Management of Advanced Prostate Cancer: Current Concepts

Prostate cancer has become a major public health burden worldwide and its incidence rates are increasing in India.  Hormonal therapy or androgen...

Email this page
Solifenacin succinate (Soliact)

The overall prevalence of overactive bladder (OAB) in men and women over the age of 40 years is 16.6%. Anticholinergic therapy is currently a...

Email this page

Our Publications

Update on Urolithiasis: Evaluation of Relation between Renal Papillary Abnormalities with Stone Composition and Description into a New Classification by Flexible Ureteroscopy

This update on urolithiasis described the incidence of papillary abnormalities in patients undergoing flexible ureteroscopy and its relation with...

Update on Urolithiasis: Evaluation of the Association of Obesity with Perioperative Outcomes following PCNL in Patients with Kidney Stones

This update on urolithiasis evaluated the association of obesity with adverse outcomes following percutaneous nephrolithotomy.

UTI: Physician Update

Physician update (issue 3) takes you through the recent news & information related to Urinary Tract Infections (UTI) followed by the various...

Role of Pyridoxine in Management of Urolithiasis

This literature provides information on role of pyridoxine in prevention of recurrence of calcium oxalate stones.

Patient Education

All You Wanted to Know about Prostate Cancer

Prostate is one of the most common cancers in men. This material describes risk factors, symptoms, diagnosis and treatment of prostate cancer. Also,...


Explore >>

Currently there is no content under this category.


Which testosterone preparation do you prefer in your patients with late onset hypogonadism?
Testosterone Cypionate/Enanthate
14% (1 vote)
Testosterone undecanoate injection
43% (3 votes)
Testosterone decanoate + testosterone isocaproate + testosterone phenpropionate + testosterone propionate injection
14% (1 vote)
Oral testosterone undecanoate
29% (2 votes)
Testosterone gel
0% (0 votes)
Total votes: 7